- New
- Research Article
- 10.1016/j.ast.2026.112197
Orbit-Structure-Contact dynamics modeling and simulation for virtual validation of active debris removal by space robots
- Oct 01, 2026
- Aerospace Science and Technology
- Jianfeng Lu + 5 more +5
Publications from 2021 to 2026
Showing 10 of 19,683 papers
Orbit-Structure-Contact dynamics modeling and simulation for virtual validation of active debris removal by space robots
Applying quantum error-correcting codes for fault-tolerant blind quantum cloud computation
Flexible biodegradable wireless battery-free integrated theranostic adhesive patch.
A knowledge-driven self-supervised learning method for enhancing EEG-based emotion recognition.
Integrated optical wireless positioning and multi-user communication based on petal-shift keying structured beams
Three decades of evolution: Key research trends in Tourism Management
Molecular mechanisms of fatty acids influence on bio-imprinted Rhizomucor miehei lipase towards 1,3-dioleoyl-2-palmitoyl glycerol synthesis
EFFECTIVENESS OF DISINFECTION METHODS FOR TOOTHBRUSHES: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Nature-based solutions in coastal urbanization: Addressing environmental and socio-economic challenges
Synthesis and characterization of bicyclo[1.1.0]butane amides and 5-methylene-3-azabicyclo[5.1.0]octan-4-ones as covalent modifiers.
Covalent inhibitors have re-emerged as powerful therapeutic agents, offering the ability to modulate "undruggable" proteins including oncogenic drivers that have eluded traditional drug discovery efforts. Expanding the repertoire of electrophilic moieties remains a critical frontier in covalent drug discovery. Here, we report a Rh(I)-catalyzed cycloisomerization of N-allyl bicyclo[1.1.0]butane amides (BCB amides) to access the 5-methylene-3-azabicyclo[5.1.0]octan-4-one (MABO) scaffold via strain-release reactivity. Both N-allyl BCB amides and MABOs can react with nucleophiles, highlighting their potential as electrophilic moieties for covalent drug design. Kinetic assays against glutathione revealed that selected N-allyl BCB amides and MABOs exhibit half-lives comparable to that of (±)-sotorasib, whose enantiomerically pure form received FDA approval as an anticancer drug. Biological evaluation in human-derived head and neck squamous cell carcinoma (HNSCC) models identified specific BCB amides and MABO compounds capable of modulating cancer cell growth. The toxicity of the compounds was evaluated by flow cytometry in human peripheral blood mononuclear cells (PBMCs) and by monitoring LDH release in the monocytic cell line THP-1, both under basal and activated conditions. Together, these findings suggest that BCB amides and MABOs represent promising classes of electrophilic scaffolds for covalent drug discovery.
Read more